Urtti A - Search Results

1

Formulation and stability of cytokine therapeutics.

Lipiäinen T, Peltoniemi M, Sarkhel S, Yrjönen T, Vuorela H, Urtti A, Juppo A. Lipiäinen T, et al. Among authors: urtti a. J Pharm Sci. 2015 Feb;104(2):307-26. doi: 10.1002/jps.24243. Epub 2014 Dec 9. J Pharm Sci. 2015. PMID: 25492409 Review.

2

Drug permeation in biomembranes: in vitro and in silico prediction and influence of physicochemical properties.

Mälkiä A, Murtomäki L, Urtti A, Kontturi K. Mälkiä A, et al. Among authors: urtti a. Eur J Pharm Sci. 2004 Sep;23(1):13-47. doi: 10.1016/j.ejps.2004.05.009. Eur J Pharm Sci. 2004. PMID: 15324921 Review.

3

Level A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series.

Kortejärvi H, Malkki J, Marvola M, Urtti A, Yliperttula M, Pajunen P. Kortejärvi H, et al. Among authors: urtti a. J Pharm Sci. 2006 Jul;95(7):1595-605. doi: 10.1002/jps.20592. J Pharm Sci. 2006. PMID: 16732564

4

Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2.

del Amo EM, Urtti A, Yliperttula M. del Amo EM, et al. Among authors: urtti a. Eur J Pharm Sci. 2008 Oct 2;35(3):161-74. doi: 10.1016/j.ejps.2008.06.015. Epub 2008 Jul 5. Eur J Pharm Sci. 2008. PMID: 18656534 Review.

5

Effluxing ABC transporters in human corneal epithelium.

Vellonen KS, Mannermaa E, Turner H, Häkli M, Wolosin JM, Tervo T, Honkakoski P, Urtti A. Vellonen KS, et al. Among authors: urtti a. J Pharm Sci. 2010 Feb;99(2):1087-98. doi: 10.1002/jps.21878. J Pharm Sci. 2010. PMID: 19623615 Free PMC article.

6

Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models.

Linnankoski J, Mäkelä J, Palmgren J, Mauriala T, Vedin C, Ungell AL, Lazorova L, Artursson P, Urtti A, Yliperttula M. Linnankoski J, et al. Among authors: urtti a. J Pharm Sci. 2010 Apr;99(4):2166-75. doi: 10.1002/jps.21961. J Pharm Sci. 2010. PMID: 19827099

7

Analysis of cause of failure of new targeting peptide in PEGylated liposome: molecular modeling as rational design tool for nanomedicine.

Lehtinen J, Magarkar A, Stepniewski M, Hakola S, Bergman M, Róg T, Yliperttula M, Urtti A, Bunker A. Lehtinen J, et al. Among authors: urtti a. Eur J Pharm Sci. 2012 Jun 14;46(3):121-30. doi: 10.1016/j.ejps.2012.02.009. Epub 2012 Feb 20. Eur J Pharm Sci. 2012. PMID: 22381076

8

Expression without boundaries: cell-free protein synthesis in pharmaceutical research.

Casteleijn MG, Urtti A, Sarkhel S. Casteleijn MG, et al. Among authors: urtti a. Int J Pharm. 2013 Jan 2;440(1):39-47. doi: 10.1016/j.ijpharm.2012.04.005. Epub 2012 Apr 11. Int J Pharm. 2013. PMID: 22521712 Review.

9

Prediction of the vitreal half-life of small molecular drug-like compounds.

Kidron H, Del Amo EM, Vellonen KS, Urtti A. Kidron H, et al. Among authors: urtti a. Pharm Res. 2012 Dec;29(12):3302-11. doi: 10.1007/s11095-012-0822-5. Epub 2012 Jul 10. Pharm Res. 2012. PMID: 22777295

10

Pharmacokinetic simulations to explore dissolution criteria of BCS I and III biowaivers with and without MDR-1 efflux transporter.

Kortejärvi H, Malkki J, Shawahna R, Scherrmann JM, Urtti A, Yliperttula M. Kortejärvi H, et al. Among authors: urtti a. Eur J Pharm Sci. 2014 Sep 30;61:18-26. doi: 10.1016/j.ejps.2014.02.004. Epub 2014 Feb 22. Eur J Pharm Sci. 2014. PMID: 24566614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

369 results

Search Page

Filters